Abstract
The clinical treatment of several hematological tumors has been revolutionized by chimeric antigen receptors T cells (CAR T) targeting antigens expressed at the surface of tumor cells to eradicate them. However, its performance is still below expectations against solid tumors, mainly due to the inefficient migration and transit of CAR T cells in these tumor sites and the frequent local im…